{
  "thread": {
    "uuid": "495cc2f9d22eb8a694d8b27b99960c45a60eb326",
    "url": "https://www.marketscreener.com/quote/stock/TEMPEST-THERAPEUTICS-INC-124221532/news/Tempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924",
    "site_full": "www.marketscreener.com",
    "site": "marketscreener.com",
    "site_section": "https://marketscreener.com/news/companies/new-products/",
    "site_categories": [
      "photography",
      "hobbies_and_interests"
    ],
    "section_title": "Stock Market Listed Companies News - MarketScreener",
    "title": "Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications -April 04, 2024 at 08:00 am EDT | MarketScreener",
    "title_full": "Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications -April 04, 2024 at 08:00 am EDT | MarketScreener",
    "published": "2024-04-04T16:00:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "DE",
    "main_image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
    "performance_score": 0,
    "domain_rank": 3920,
    "domain_rank_updated": "2024-04-02T13:08:08.000+03:00",
    "reach": null,
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "gplus": {
        "shares": 0
      },
      "pinterest": {
        "shares": 0
      },
      "linkedin": {
        "shares": 0
      },
      "stumbledupon": {
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "495cc2f9d22eb8a694d8b27b99960c45a60eb326",
  "url": "https://www.marketscreener.com/quote/stock/TEMPEST-THERAPEUTICS-INC-124221532/news/Tempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924",
  "ord_in_thread": 0,
  "parent_url": null,
  "author": "MarketScreener",
  "published": "2024-04-04T16:00:00.000+03:00",
  "title": "Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications -April 04, 2024 at 08:00 am EDT | MarketScreener",
  "text": "Tempest Therapeutics, Inc. announced that Cancer Research Communications published positive clinical data from the dose-escalation Phase 1 trial of TPST-1120 in an article titled \"First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARa, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors\". The data showed that TPST-1120 demonstrated clinical activity, including tumor shrinkage, even in PD-1 inhibitor refractory and immune compromised cancers, and was well tolerated both as monotherapy and in combination with nivolumab. These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 In combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.\nTPST-1120 Phase 1 Study: In this first-in-human Phase 1 study, 35 patients were treated with escalating doses of TPST-1120 either as monotherapy (20 patients) or in combination with the anti-PD-1 therapy, nivolumab (15 patients). TPST-1120 was well-tolerated as monotherapy and in combination, with a maximum tolerated dose not identified and predominantly low-grade toxicity. Notwithstanding the late-line stage of these patients and difficult to treat tumor types, clinical benefit was observed as both a monotherapy and combination.2 In monotherapy, a best response of stable disease (SD) was observed in 53% (10/19) of evaluable patients, with 5 of those patients staying on treatment for more than 5 months.\nTumor shrinkage of target lesions on treatment occurred in 21% (4 patients) and a best response of no target lesion growth was seen in 3 additional patients. In the combination therapy cohorts, including patients with heavily pretreated cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), the objective response rate (ORR) was 23% (3/13, all partial responses, or PRs) across all dose levels and 30% (3/10) at the two highest dose levels of TPST-1120, suggesting dose-responsive anti-cancer activity. These responses included a 50% ORR in patients with RCC (2/4 evaluable) who had previously progressed on anti-PD-1 therapy, and one patient with heavily pre-treated CCA.\nAnalysis of whole blood specimens revealed changes in expression of PPARa-associated immune genes that were related to TPST-1120 dose levels. Some of these changes were only observed in patients who had partial responses, linking TPST-1120 biological activity to clinical outcome.\nShare Â© S&P Capital IQ - 2024",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Science and Technology",
    "Health"
  ],
  "external_links": [
    "https://telegram.me/share/url?url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dtelegram%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
    "https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Tempest",
    "https://twitter.com/intent/tweet?text=Tempest",
    "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
    "https://wa.me/?text=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dwhatsapp%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
    "https://www.telegram.me/share/url?url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dtelegram%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
    "https://facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
    "https://www.twitter.com/intent/tweet?text=Tempest",
    "https://telegram.me/share/url",
    "https://www.linkedin.com/shareArticle",
    "https://www.wa.me/?text=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dwhatsapp%26utm_medium%3Dsocial%26utm_campaign%3Dshare",
    "https://wa.me/",
    "https://www.facebook.com/sharer/sharer.php",
    "https://linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FTEMPEST-THERAPEUTICS-INC-124221532%2Fnews%2FTempest-Therapeutics-Inc-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-46365924%2F%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Tempest",
    "https://twitter.com/intent/tweet"
  ],
  "external_images": [],
  "entities": {
    "persons": [
      {
        "name": "nivolumab",
        "sentiment": "none"
      }
    ],
    "organizations": [
      {
        "name": "tempest therapeutics, inc",
        "sentiment": "neutral"
      },
      {
        "name": "announces publication of positive data",
        "sentiment": "neutral"
      },
      {
        "name": "cancer research communications",
        "sentiment": "neutral"
      },
      {
        "name": "journal of cancer research communications",
        "sentiment": "neutral"
      },
      {
        "name": "tpst",
        "sentiment": "neutral"
      },
      {
        "name": "marketscreener tempest therapeutics, inc.",
        "sentiment": "neutral"
      },
      {
        "name": "hcc",
        "sentiment": "none"
      }
    ],
    "locations": []
  },
  "rating": null,
  "crawled": "2024-04-05T00:14:03.997+03:00",
  "updated": "2024-04-05T00:14:03.997+03:00"
}